AACR 2023
DURHAM, NC and AUSTIN, TX – October 14, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the closing of its upsized initial public offering of 13,664,704 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,782,352 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Shattuck from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, were approximately $232.3 million. All of the shares in the offering were offered by Shattuck. The shares began trading on The Nasdaq Global Select Market on October 9, 2020 under the ticker symbol “STTK.”
Citigroup, Cowen, and Evercore ISI acted as joint book-running managers for the offering. Needham & Company acted as lead manager for the offering.
The registration statements relating to these securities became effective on October 8, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by telephone at (833) 297-2926; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
DURHAM, NC and AUSTIN, TX – October 8, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the pricing of its upsized initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Shattuck from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, are expected to be approximately $202 million. All of the shares are being offered by Shattuck. The shares are expected to begin trading on The Nasdaq Global Select Market on October 9, 2020 under the ticker symbol “STTK.” In addition, Shattuck has granted the underwriters a 30-day option to purchase up to an additional 1,782,352 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on October 14, 2020 subject to the satisfaction of customary closing conditions.
Citigroup, Cowen, and Evercore ISI are acting as joint book-running managers for the offering. Needham & Company is acting as lead manager for the offering.
The registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on October 8, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by telephone at (833) 297-2926; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
DURHAM, NC and AUSTIN, TX – September 1, 2020 – Shattuck Labs, Inc. (“Shattuck”), an innovative clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform to develop an entirely new class of biologic medicines for the treatment of cancer and autoimmune disease, today announced its presentation at the PEGS Summit 2020 being held virtually August 31 – September 4, 2020.
Presentation Details
Presentation Title: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity
Presentation Subtitle: Preclinical and Clinical Development of SL-172154
Date/Time: September 4at 11:10 a.m. EDT
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Location: https://www.pegsummit.com/
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform, to develop an entirely new class of bi-functional fusion proteins with applications in oncology and autoimmune disease. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to simultaneously block the CD47 immune checkpoint and agonize the tumor necrosis factor (TNF) CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: http://www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
DURHAM, NC and AUSTIN, TX – August 31, 2020 –Shattuck Labs, Inc. (“Shattuck”), an innovative clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform to develop an entirely new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced initiation of a Phase 1 clinical trial of its compound SL-172154 (SIRPα-Fc-CD40L), a bi-functional fusion protein that simultaneously blocks the CD47/SIRPα checkpoint and activates the tumor necrosis factor (TNF) costimulatory receptor CD40.
“SL-172154 is our lead wholly owned product candidate and a potentially best-in-class CD47 checkpoint inhibitor, a recently clinically validated target for cancer immunotherapy,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “In preclinical studies, SL-172154 demonstrated superior anti-tumor activity as compared to either CD47- or CD40-targeted antibodies, either alone or in combination. Based on its ability to simultaneously block the CD47/SIRPα checkpoint and activate the CD40 costimulatory receptor, we believe SL-172154 offers a promising approach to treating patients with ovarian cancer and a range of other cancer types.”
The Phase 1 clinical trial is a multicenter, open-label, dose-escalation study. The study will evaluate the safety, tolerability, pharmacokinetics, anti-tumor, and pharmacodynamic effects of SL-172154. Initial clinical data from the trial are expected in the second half of 2021. In addition, Shattuck plans to evaluate SL-172154 in combination with other therapeutic agents in specific cancers.
“CD47/SIRPα checkpoint blocking therapeutics have emerged as promising immuno-oncology therapies. We are incredibly excited to have now initiated this clinical trial evaluating SL-172154 in patients with ovarian cancer, where there remains a high unmet need for effective new therapies,” said Lini Pandite, M.D., Chief Medical Officer of Shattuck.
About SL-172154
SL-172154 is a bi-functional fusion protein designed to simultaneously inhibit the CD47/SIRPα checkpoint and activate the TNF costimulatory receptor CD40. In preclinical studies, SL-172154 demonstrated the ability to bridge the innate and adaptive immune response by simultaneously blocking the CD47 macrophage “don’t eat me” signal and agonizing CD40 to induce a T cell-mediated immune response, or “eat me” signal.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform to develop an entirely new class of bi-functional fusion proteins with applications in oncology and autoimmune disease. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the TNF CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: http://www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
DURHAM, NC and AUSTIN, TX – July 21, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune disease, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau most recently served as Chief Operating Officer at the Bill & Melinda Gates Medical Research Institute. She will replace Wally Loewenbaum, who is stepping down from the Board of Directors.
“Helen is a proven leader in the pharmaceutical and biotechnology industry with a distinguished track record and deep expertise in corporate strategy, financial management, and operations,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “She is joining our Board at an exciting time, on the heels of our recent $118 million Series B financing, and we look forward to leveraging her experience as we advance the next program from our ARC platform, SL-172154, which combines CD47 inhibition with CD40 co-stimulation, in two Phase 1 clinical trials.”
“I am delighted to join the board and have been very impressed by the depth and versatility of Shattuck’s pipeline,” said Ms. Boudreau. “I look forward to working with the Board and management on Shattuck’s strategy and growth initiatives in the years ahead.”
Prior to her tenure at the Bill & Melinda Gates Medical Research Institute, Ms. Boudreau served as the Chief Financial Officer of Proteostasis Therapeutics, where she led the finance and accounting functions, and immediately before that she served as the Chief Financial Officer of Forma Therapeutics. From 2008 to 2014, she held a variety of leadership roles at Novartis, ultimately serving as the Chief Financial Officer of Novartis Corporation in the US. Prior to joining Novartis, she held multiple leadership positions at Pfizer, and strategic and operational roles at Yum Brands/PepsiCo., McKinsey & Company, and Bank of America. Ms. Boudreau received a B.A. in Economics from the University of Maryland and an M.B.A. from the Darden School at the University of Virginia.
“We want to thank Wally for his service to Shattuck since our formation,” said Josiah Hornblower, Shattuck’s founder and Executive Chairman. “As one of our earliest investors, he has made significant contributions to Shattuck’s Board of Directors, and we are very grateful for his guidance.”
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform, a novel class of bi-functional fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. A second compound, SL-172154 (SIRPα-Fc-CD40L), will begin enrollment in two Phase 1 trials in 2020. Shattuck’s ARC platform enables a unique consolidation of checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: http://www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune disease, today announced the closing of a $118 million Series B equity financing. Redmile Group was the lead investor, with other new investors including Janus Henderson Investors, Fidelity Management & Research Company, LLC, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective, and Piper Sandler & Co., as well as participation from existing investors.
“Over the past four years we have pioneered the development of our proprietary ARC technology platform, which consolidates checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics, tackling many of the risks associated with a new biologics platform along the way,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “The support from this syndicate of experienced life science investors will accelerate clinical development of multiple programs aimed to establish ARC therapeutics as an entirely new class of biologic medicine.”
The proceeds from the financing will be used to support the continued clinical development of SL-172154 (SIRPα-Fc-CD40L), a wholly-owned fusion protein that combines CD47 inhibition with CD40 co-stimulation, and SL-279252 (PD1-Fc-OX40L), Shattuck’s lead PD1 asset being developed in collaboration with Takeda Pharmaceuticals. Shattuck anticipates adding another clinical program in 2021 and continuing the development of an innovative pipeline of compounds for the treatment of cancer and autoimmune disease.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. A second compound, SL-172154 (SIRPα-Fc-CD40L), will begin enrollment in a Phase I trial in 2020. Shattuck’s ARC platform enables a unique consolidation of checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: https://www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
AUSTIN, Texas – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced that Shattuck Labs’ Chief Executive Officer, Taylor Schreiber, M.D., Ph.D., will present at the 40th Annual Cowen Health Care Conference on Wednesday, March 4 at 9:30 a.m. ET in Boston.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and other diseases. The Company’s lead investigational new medicine SL-279252 (PD1-Fc-OX40L), a proprietary bi-functional fusion protein, has the potential to be a best-in-class therapy for solid tumors and lymphomas. Using its ARC platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: https://www.shattucklabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Daniella Funaro
Stern Investor Relations, Inc.
212-362-1200
Daniella.Funaro@sternir.com
AUSTIN, Texas–(BUSINESS WIRE)–Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced the appointment of Shattuck’s Chief Scientific Officer and Co-founder, Taylor Schreiber, M.D., Ph.D., to Chief Executive Officer. Dr. Schreiber succeeds Josiah Hornblower, who will continue to work with and advise the Company in his role as Executive Chairman of the Board of Directors.
“I am grateful to have this opportunity to serve as CEO of Shattuck and build upon the tremendous foundation set by Josiah. It is an exciting time for the Company, and the initial Phase 1 clinical trial data from our lead program, SL-279252 (PD1-Fc-OX40L), partnered with Takeda, indicates that ARCs may have unlocked an important class of immune activating receptors,” said Taylor Schreiber, M.D., Ph.D. “With several hundred therapeutic candidates derived from the ARC platform technology, Shattuck is poised to rapidly advance product candidates with best-in-class potential toward virtually any target in immuno-oncology which is clinically de-risked by traditional antibody modalities.” “It has been a privilege to lead this incredible team through the foundational stages of developing potentially transformative biologics,” said Josiah Hornblower. “As the lead inventor of our first-in-class ARC platform technology, Taylor is well-suited to lead the Company through this next phase of growth. His strong scientific background, passion for the Shattuck vision, and dedication to helping patients will be invaluable as Shattuck achieves clinical proof of concept and demonstrates the disruptive potential of ARC therapeutics as compared to traditional antibody therapies.”
Dr. Schreiber co-founded Shattuck in 2016 and previously served as the Chief Scientific Officer. Prior to Shattuck, he co-invented several technologies, including TNFRSF25 agonist technology developed by Pelican Therapeutics, where he served as Chairman of the Scientific Advisory Board. He received his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.
About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and other diseases. The Company’s lead investigational new medicine SL-279252 (PD1-Fc-OX40L), a proprietary bi-functional fusion protein, has the potential to be a best-in-class therapy for solid tumors and lymphomas. Using its ARC platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: https://www.shattucklabs.com.
Investor Contact:
Andrew R. Neill
VP, Corporate Development and Strategy
Shattuck Labs, Inc.
investors@shattucklabs.com
Media Contact:
Daniella Funaro
Stern Investor Relations, Inc.
212-362-1200
Daniella.Funaro@sternir.com
